Pharmaceuticals enable us to lead healthier, longer lives . . . most of the time.
Research supports allegations that Risperdal may cause the development of breasts (gynecomastia) in young males. When given to adolescent boys at doses commonly used for the treatment of psychotic symptoms, the hormone prolactin is produced at abnormally high levels. Prolactin stimulates breast development. In addition to noticeable breast tissue, gynecomastia causes pain, nipple discharge, and psychological trauma.
Some adolescent males who suffer from gynecomastia have had to undergo surgery. Mild cases can be treated with liposuction, but more severe cases require a mastectomy and surgical removal of excess skin.
Another consequence of the Risperdal-induced prolactin stimulation has been observed in young girls, before the age of puberty, who begin to lactate, or produce milk.
More than 420 lawsuits have been filed against Johnson & Johnson, the pharmaceutical company that manufactures Risperdal, and at least 130 involve allegations that Risperdal (risperidone) resulted in gynecomastia and that the manufacturer failed to warn them of such risks. In many cases, patients took Risperdal for years without knowing that gynecomastia could result.
If you suspect that you or someone you love has suffered from gynecomastia as a result of taking Risperdal, contact Pogust Braslow & Millrood for a confidential consultation. Our mission is to protect those who are injured by the negligence or misconduct of others – including pharmaceutical companies. You can reach our attorneys online.